Last reviewed · How we verify
Hemay022+AI
Hemay022+AI is an anti-PD-L1 monoclonal antibody combined with an AI-optimized therapeutic approach to enhance immune checkpoint inhibition and anti-tumor immunity.
Hemay022+AI is an anti-PD-L1 monoclonal antibody combined with an AI-optimized therapeutic approach to enhance immune checkpoint inhibition and anti-tumor immunity. Used for Non-small cell lung cancer, Other solid tumors (specific indications under investigation in Phase 3).
At a glance
| Generic name | Hemay022+AI |
|---|---|
| Sponsor | Tianjin Hemay Pharmaceutical Co., Ltd |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Hemay022 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby restoring anti-tumor immune responses. The '+AI' designation suggests integration of artificial intelligence in patient selection, dosing optimization, or combination strategy design to improve therapeutic efficacy and safety outcomes.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (specific indications under investigation in Phase 3)
Common side effects
- Fatigue
- Decreased appetite
- Immune-related adverse events (irAEs)
- Pneumonitis
- Hepatotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hemay022+AI CI brief — competitive landscape report
- Hemay022+AI updates RSS · CI watch RSS
- Tianjin Hemay Pharmaceutical Co., Ltd portfolio CI